You are invited to the upcoming Research Grand Rounds on “A New Wave of Medicine: Marine Natural Products and Enabling Technologies”.
About the Event
A large proportion of the current drug traces back to nature. Biodiversity in the Earth’s largest habitat, the ocean, is greater than that on land, suggesting a huge potential for drug discovery. In contrast to synthetic drugs, natural products are genome-encoded, which provides unique opportunties. Furthermore they are oftentimes ultrapotent and possess new mechanisms of action, which could translate into best-in-class or first-in-class agents. Advancements in screening characterisation, and delivery technologies have renewed interest in marine-derived drugs to address unmet clinical needs.
Hear from Prof Luesch and Dr Yeung as they dive into the oceans of opportunity in natural product drug discovery.
About the Speakers
Prof Hendrik Luesch is the Professor of the Programme in Cancer and Stem Cell Biology at Duke-NUS Medical School. He has over two decades of experience in academic drug discovery and co-founded several companies. He leads a comprehensive multidisciplinary marine natural products programme with function-driven chemistry and genomics-based discovery platforms. His research highlights include the discovery of the microtubule-destabiliser dolastatin 10 from a marine cyanobacterium, pinponting the source of this important compound.
Dr Bryan K.S. Yeung is the Vice President of Bioconjugation and Chemistry at Axcynsis Therapeutics. He is a pharmaceutical researcher and drug discovery expert with over two decades of industry experience. Specialising in medicinal chemistry, he has led multiple discovery stage programmes in oncology and infectious diseases resulting in significant constributions bringing new drugs candidates for malaria and dengue into the clinic.
About the Facilitator
Prof Damian O’Connell is the Chief Executive Officer at Experimental Drug Development Centre (EDDC). He is also a board member of the INFANT Research centre in Ireland and member of several medical societies such as British Pharmacological Society, Drug Safety Executive Council (DSEC), the American Society for Clinical Pharmacology and Therapeutics. He previously held senior positions within Bayer, Pfizer Research and Development, Parke Davis, Elan Pharmaceuticals and Neurex. He is also a Fellow of both The Royal Society of Medicine and The Royal Academy of Medicine (Ireland).
Registration Details
Sign up
here now or scan the QR code in the poster below.
